Review: Diagnosis and management of gout in the long-term care setting

Annals of Long-Term Care

Volumn 15, Issue 5, 2007, Pages 34-40

  Singh, Harinder ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; FENOFIBRATE; INFLIXIMAB; LOSARTAN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PREDNISONE; PROBENECID; PURINE; STEROID; SULFINPYRAZONE; TRIAMCINOLONE ACETONIDE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ASPIRATION BIOPSY; CATARACT; DIARRHEA; DRUG MONITORING; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; GOUT; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY INJURY; LIVER INJURY; LONG TERM CARE; OSTEOPOROSIS; PEPTIC ULCER; RADIODIAGNOSIS; RASH; REVIEW; SYNOVIAL FLUID; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VASCULITIS;

EID: 34250316503     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Ene-Stroescu D, Gorbien MJ. Gouty arthritis. A primer on late-onset gout. Geriatrics 2005;60(7):24-31.
2. Wallace K, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-1587.
3. Brauner DJ, Sorensen LB, Ellman MH. Rheumatologic diseases. In: Cassel CK, ed. Geriatric Medicine: An Evidence Based Approach. 4th ed. New York: Springer-Velag; 2003:573-619.
4. Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging 1998;13(3):229-243.
5. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-934.
6. Gutman AB. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum 1973;16:431-445.
7. Nakayama DA, Barthelemy C, Carrera G, et al. Tophaceous gout: A clinical and radiographic assessment. Arthritis Rheum 1984;27:468-471.
8. Underwood M. Diagnosis and management of gout. BMJ 2006;332(7553): 1315-1319.
9. Kozin F, McCarty DJ. Rheumatoid factors in the serum of gouty patients. Arthritis Rheum 1977;20:1559-1560.
10. Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol 1991;18:1232-1234.
11. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20(3):895-900.
12. American College of Physicians. PIER: Physicians' Information and Education Resource. Available at: http://pier.acponline.org/index.html. Accessed February 12, 2007.
13. Yu JS, Chung C, Recht M, et al. MR imaging of tophaceous gout. Am J Roentgenol 1997;168(2):523-527.
14. Agudelo CA. Gout and hyperuricemia. Curr Opin Rheumatol 1989;1:286-293.
15. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991;50:263-266.
16. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349(17):1647- 1655.
17. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-1327.
18. Morris I, Varughese G, Mattingly P. Colchicine in acute gout BMJ 2003;327: 275-276.
19. Croft JD. Discussion following cases 4 and 5. Am J Med 2006;119(11 Suppl 1):S16-S19.
20. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002;22(4):385-387.
21. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-18.
22. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-451.
23. Finley JM. Case 8: Initiation of urate-lowering therapy for standard advanced gout. Am J Med 2006;119(11 Suppl 1):S25-S28.
24. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56(5):1879-1885. [Erratum in: Kidney Int 2000;57(1):370.]
25. Tausche AK, Richter K, Grässler A, et al. Severe gouty arthritis refractory to anti-inflammatory drugs: Treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 2004;63:1351-1352.
26. Fiehn C. Zeier M. Successful treatment of chronic tophaceous gout with infliximab (Remicade). Rheumatol Int 2006;26(3):274-276. Epub 2005 Jan 3.
27. Medellin M, Erckson A, Enzenauer R. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol 1997;3:24-27.